Literature DB >> 21209238

Fangjiomics: in search of effective and safe combination therapies.

Zhong Wang1, Jun Liu, Yiyu Cheng, Yongyan Wang.   

Abstract

Millennia-old Chinese medicine treats disease with many combination therapies involving ingredients used in clinic practice. Fangjiomics is the science of identifying and designing effective mixtures of bioactive agents and elucidating their modes of action beyond those of Chinese patent medicines. Omics profiling and quantitative optimal modeling have been used to associate the various responses with biological pathways related to disease phenotype. Fangjiomics seeks to study myriad compatible combinations that may act through multiple targets, modes of action, and biological pathways balancing on off-target and on-target effects. This approach may lead to the discovery of controllable array-designed therapies to combine less potent elements that are more effective collectively but have fewer adverse side effects than does any element singly.

Mesh:

Year:  2011        PMID: 21209238     DOI: 10.1177/0091270010382913

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  16 in total

1.  Convergence: Where West meets East.

Authors:  Peng Tian
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

Review 2.  Diverse array-designed modes of combination therapies in Fangjiomics.

Authors:  Jun Liu; Zhong Wang
Journal:  Acta Pharmacol Sin       Date:  2015-04-13       Impact factor: 6.150

3.  Fangjiomics: revealing adaptive omics pharmacological mechanisms of the myriad combination therapies to achieve personalized medicine.

Authors:  Dayue Darrel Duan; Zhong Wang; Bo-li Zhang; Yong-yan Wang
Journal:  Acta Pharmacol Sin       Date:  2015-06       Impact factor: 6.150

4.  Deciphering the therapeutic mechanisms of Xiao-Ke-An in treatment of type 2 diabetes in mice by a Fangjiomics approach.

Authors:  Zhen-zhong Yang; Wei Liu; Feng Zhang; Zheng Li; Yi-yu Cheng
Journal:  Acta Pharmacol Sin       Date:  2015-05-11       Impact factor: 6.150

5.  Yangxin Tongmai Formula ameliorates impaired glucose tolerance in children with Graves' disease through upregulation of the insulin receptor levels.

Authors:  Yan-Hong Luo; Min Zhu; Dong-Gang Wang; Yu-Sheng Yang; Tao Tan; Hua Zhu; Jian-Feng He
Journal:  Acta Pharmacol Sin       Date:  2017-11-23       Impact factor: 6.150

6.  Phenotype-dependent alteration of pathways and networks reveals a pure synergistic mechanism for compounds treating mouse cerebral ischemia.

Authors:  Peng-qian Wang; Bing Li; Jun Liu; Ying-ying Zhang; Ya-nan Yu; Xiao-xu Zhang; Ye Yuan; Zhi-li Guo; Hong-li Wu; Hai-xia Li; Hai-xia Dang; Shan-shan Guo; Zhong Wang
Journal:  Acta Pharmacol Sin       Date:  2015-05-11       Impact factor: 6.150

7.  Editorial: Combination Therapy of Vascular Diseases and Fangjiomics: When West Meets East in the Era of Phenomics.

Authors:  Zhong Wang; Dayue Darrel Duan; Yong-Yan Wang
Journal:  Curr Vasc Pharmacol       Date:  2015       Impact factor: 2.719

8.  Pure mechanistic analysis of additive neuroprotective effects between baicalin and jasminoidin in ischemic stroke mice.

Authors:  Peng-Qian Wang; Qiong Liu; Wen-Juan Xu; Ya-Nan Yu; Ying-Ying Zhang; Bing Li; Jun Liu; Zhong Wang
Journal:  Acta Pharmacol Sin       Date:  2018-01-18       Impact factor: 6.150

9.  A comparative pharmacogenomic analysis of three classic TCM prescriptions for coronary heart disease based on molecular network modeling.

Authors:  Ying-Ying Zhang; Zi-de Zhao; Peng-Yun Kong; Lin Gao; Ya-Nan Yu; Jun Liu; Peng-Qian Wang; Bing Li; Xiao-Xu Zhang; Li-Qiang Yang; Zhong Wang
Journal:  Acta Pharmacol Sin       Date:  2020-02-12       Impact factor: 6.150

10.  Therapeutic effect of Jinzhen oral liquid for hand foot and mouth disease: a randomized, multi-center, double-blind, placebo-controlled trial.

Authors:  Jun Liu; Guo-Liang Zhang; Gui-Qin Huang; Li Li; Chun-Ping Li; Mei Wang; Xiao-Yan Liang; Di Xie; Chang-Ming Yang; Yan Li; Xiu-Rong Sun; Hong-Sen Zhang; Bai-Song Wan; Wei-Hua Zhang; Hao Yu; Ru-Yang Zhang; Ya-Nan Yu; Zhong Wang; Yong-Yan Wang
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.